Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del‐CFTR by a CDK‐independent mechanism

The most common mutation in cystic fibrosis (CF), F508del, causes defects in trafficking, channel gating and endocytosis of the CF transmembrane conductance regulator (CFTR) protein. Because CF is an orphan disease, therapeutic strategies aimed at improving mutant CFTR functions are needed to target the root cause of CF.

[1]  M. Wilke,et al.  Rescue of functional delF508‐CFTR channels in cystic fibrosis epithelial cells by the α‐glucosidase inhibitor miglustat , 2006, FEBS letters.

[2]  L. Meijer,et al.  Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives* , 2005, Journal of Biological Chemistry.

[3]  J. Wakefield,et al.  Failure of cAMP agonists to activate rescued ΔF508 CFTR in CFBE41o– airway epithelial monolayers , 2005, The Journal of physiology.

[4]  R. Frizzell,et al.  Rescue of dysfunctional deltaF508-CFTR chloride channel activity by IBMX. , 1999, The Journal of membrane biology.

[5]  Melanie A. Jones,et al.  Mechanisms of Pharmacological Rescue of Trafficking-defective hERG Mutant Channels in Human Long QT Syndrome* , 2006, Journal of Biological Chemistry.

[6]  L. Meijer,et al.  CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. , 2010, Genes & cancer.

[7]  M. Salto‐Tellez,et al.  Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer , 2009, Clinical Cancer Research.

[8]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[9]  P. Workman,et al.  A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.

[10]  Adam J Pawson,et al.  The Concise Guide to Pharmacology 2013/14: Ion Channels , 2013, British journal of pharmacology.

[11]  John D. Venable,et al.  Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis , 2006, Cell.

[12]  M. Amaral,et al.  Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin , 2005, Molecular and Cellular Biology.

[13]  R. Horn,et al.  Panning transfected cells for electrophysiological studies. , 1993, BioTechniques.

[14]  J. Węsierska‐Gądek,et al.  Novel potent pharmacological cyclin-dependent kinase inhibitors. , 2009, Future medicinal chemistry.

[15]  Marek Michalak,et al.  Quality control in the endoplasmic reticulum. , 2010, Seminars in cell & developmental biology.

[16]  E. Herczenik,et al.  Molecular and cellular aspects of protein misfolding and disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  W. Reenstra,et al.  Prostaglandin F2alpha stimulates CFTR activity by PKA- and PKC-dependent phosphorylation. , 1998, The American journal of physiology.

[18]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[19]  R. Frizzell,et al.  Rescue of Dysfunctional ΔF508-CFTR Chloride Channel Activity by IBMX , 1999, The Journal of Membrane Biology.

[20]  David N Sheppard,et al.  The relationship between cell proliferation, Cl- secretion, and renal cyst growth: a study using CFTR inhibitors. , 2004, Kidney international.

[21]  Sheng-tian Li,et al.  Cdk5/p35 Regulates Neurotransmitter Release through Phosphorylation and Downregulation of P/Q-Type Voltage-Dependent Calcium Channel Activity , 2002, The Journal of Neuroscience.

[22]  G. Lenoir,et al.  In Cystic Fibrosis Homozygotes and Heterozygotes, Neutrophil Apoptosis Is Delayed and Modulated by Diamide or Roscovitine: Evidence for an Innate Neutrophil Disturbance , 2010, Journal of Innate Immunity.

[23]  A S Verkman,et al.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.

[24]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[25]  Sul-Hee Chung,et al.  Roscovitine increases intracellular calcium release and capacitative calcium entry in PC12 cells , 2010, Neuroscience Letters.

[26]  D. Bichet,et al.  Pharmacological chaperone action on G-protein-coupled receptors. , 2004, Current opinion in pharmacology.

[27]  M. Kester,et al.  State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. , 2009, American journal of physiology. Cell physiology.

[28]  P. Lebecque,et al.  Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. , 2009, American journal of respiratory and critical care medicine.

[29]  R. Ravazzolo,et al.  Antihypertensive 1,4-Dihydropyridines as Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating Defect Caused by Cystic Fibrosis Mutations , 2005, Molecular Pharmacology.

[30]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[31]  M. Wormald,et al.  4-C-Me-DAB and 4-C-Me-LAB - enantiomeric alkyl-branched pyrrolidine iminosugars - are specific and potent α-glucosidase inhibitors; acetone as the sole protecting group. , 2011, Tetrahedron letters.

[32]  Laurent Meijer,et al.  Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. , 2003, Accounts of chemical research.

[33]  G. Novelli,et al.  Isolation of CF cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting , 2002, Gene Therapy.

[34]  J. Olsen,et al.  Effect of Host Modification and Age on Airway Epithelial Gene Transfer Mediated by a Murine Leukemia Virus-Derived Vector , 1998, Journal of Virology.

[35]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[36]  C. Norez,et al.  A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. , 2009, American journal of respiratory cell and molecular biology.

[37]  W. Reenstra,et al.  Prostaglandin F2αstimulates CFTR activity by PKA- and PKC-dependent phosphorylation. , 1998, American journal of physiology. Cell physiology.

[38]  D. Clarke,et al.  Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. , 2004, Biochemical and biophysical research communications.

[39]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[40]  M. Sinnreich,et al.  Proteasomal Inhibition Restores Biological Function of Mis-sense Mutated Dysferlin in Patient-derived Muscle Cells* , 2012, The Journal of Biological Chemistry.

[41]  C. Barbato,et al.  Proteasome Involvement and Accumulation of Ubiquitinated Proteins in Cerebellar Granule Neurons Undergoing Apoptosis , 2000, The Journal of Neuroscience.

[42]  I. Aldoss,et al.  Seliciclib in malignancies , 2009, Expert opinion on investigational drugs.

[43]  M. Chahine,et al.  The β1-Subunit of Nav1.5 Cardiac Sodium Channel Is Required for a Dominant Negative Effect through α-α Interaction , 2012, PloS one.

[44]  J. Elborn,et al.  Neutrophils in cystic fibrosis , 2008, Thorax.

[45]  D. Clarke,et al.  Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. , 2007, The Biochemical journal.

[46]  L. Meijer,et al.  Practical Synthesis of Roscovitine and CR8 , 2009 .

[47]  K. Klinger,et al.  Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. , 1990, The American journal of physiology.

[48]  Lin Tang,et al.  Roscovitine Targets, Protein Kinases and Pyridoxal Kinase*[boxs] , 2005, Journal of Biological Chemistry.

[49]  A. Kitzis,et al.  Proteasome-Dependent Pharmacological Rescue of Cystic Fibrosis Transmembrane Conductance Regulator Revealed by Mutation of Glycine 622 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[50]  L. Meijer,et al.  Purification of CK1 by affinity chromatography on immobilised axin. , 2007, Protein expression and purification.

[51]  H. Kawasaki,et al.  Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. , 1993, Biochemical and biophysical research communications.

[52]  L. Galietta.  Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors , 2013, Pediatric Drugs.

[53]  B. Gaston,et al.  S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation. , 2001, Biochemical and biophysical research communications.

[54]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[55]  C. Tsai,et al.  Purification and Characterization , 2006 .

[56]  J. Schläpfer,et al.  Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. , 2005, Cardiovascular research.

[57]  S. Fang,et al.  Selective Inhibition of Endoplasmic Reticulum-associated Degradation Rescues ΔF508-Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels , 2006, Journal of Biological Chemistry.

[58]  X. Wang,et al.  Effects of a new cystic fibrosis transmembrane conductance regulator inhibitor on Cl− conductance in human sweat ducts , 2004, Experimental physiology.

[59]  M. Riedel,et al.  [Airway epithelial cells]. , 1991, Arerugi = [Allergy].

[60]  L Meijer,et al.  CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases , 2008, Oncogene.

[61]  John Geibel,et al.  Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells , 2002, Nature Medicine.

[62]  Amy E Palmer,et al.  Measuring calcium signaling using genetically targetable fluorescent indicators , 2006, Nature Protocols.

[63]  M. Welsh,et al.  Inhibition of the Cystic Fibrosis Transmembrane Conductance Regulator By ATP‐Sensitive K+ Channel Regulators a , 1993, Annals of the New York Academy of Sciences.

[64]  C M Harris,et al.  Sildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis , 2004, Thorax.

[65]  T. Sommer,et al.  ERAD: the long road to destruction , 2005, Nature Cell Biology.

[66]  L. Meijer,et al.  Cyclin-dependent kinase inhibitors: a survey of recent patent literature , 2010, Expert opinion on therapeutic patents.

[67]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[68]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[69]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[70]  K. Du,et al.  Curcumin, a Major Constituent of Turmeric, Corrects Cystic Fibrosis Defects , 2004, Science.

[71]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[72]  P. Zeitlin,et al.  Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. , 2000, American journal of physiology. Cell physiology.

[73]  Christopher Haslett,et al.  Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis , 2006, Nature Medicine.

[74]  John R Yates,et al.  Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.

[75]  Laurie A. Smith,et al.  Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine , 2006, Nature.

[76]  Adam J Pawson,et al.  The Concise Guide to Pharmacology 2013/14: Enzymes , 2013, British journal of pharmacology.

[77]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[78]  P. Zeitlin,et al.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. , 1998, American journal of respiratory and critical care medicine.

[79]  I. Guerrera,et al.  Coronin-1 Is Associated with Neutrophil Survival and Is Cleaved during Apoptosis: Potential Implication in Neutrophils from Cystic Fibrosis Patients1 , 2009, The Journal of Immunology.

[80]  Satoshi Omura,et al.  Degradation of CFTR by the ubiquitin-proteasome pathway , 1995, Cell.

[81]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[82]  M. Frieden,et al.  Transient Receptor Potential Canonical Channels Are Required for in Vitro Endothelial Tube Formation* , 2011, The Journal of Biological Chemistry.

[83]  J. Riordan,et al.  CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.

[84]  Fabrice Antigny,et al.  Maintaining Low Ca2+ Level in the Endoplasmic Reticulum Restores Abnormal Endogenous F508del‐CFTR Trafficking in Airway Epithelial Cells , 2006, Traffic.

[85]  B. Z. Peterson,et al.  Roscovitine Binds to Novel L-channel (CaV1.2) Sites That Separately Affect Activation and Inactivation* , 2009, The Journal of Biological Chemistry.